Zobrazeno 1 - 10
of 166
pro vyhledávání: '"Reshma Jagsi"'
Autor:
T.P. Boike, Aleksandar F. Dragovic, Robert T. Dess, Derek Bergsma, Kimberly A. Hochstedler, Michael M. Dominello, Inga S. Grills, Lori J. Pierce, Martha M. Matuszak, Daniel E. Spratt, Reshma Jagsi, P.A. Paximadis, James A. Hayman, Benjamin Movsas, Shruti Jolly, J.R. Wilkie, Matthew J. Schipper
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:942-950
Introduction: Little data have been reported about the patient experience during curative radiotherapy for lung cancer in routine clinical practice, or how this relates to treatment toxicity reported by clinicians. The purpose of this study was to co
Autor:
Eyad Abu-Isa, Frank A. Vicini, Eleanor M. Walker, Peter Paximadis, Isaac Kaufman, D P Bergsma, David K. Heimburger, Michael M. Dominello, Jeffrey D. Radawski, Amit Bhatt, Lori J. Pierce, Paul G. Kocheril, Annette E. Kretzler, Kent A. Griffith, Stephen Franklin, Joshua T. Dilworth, Reshma Jagsi
Publikováno v:
Int J Radiat Oncol Biol Phys
Purpose Questions remain about whether moderately hypofractionated whole-breast irradiation is appropriate for patients with triple-negative breast cancer. Methods and Materials Using the prospective database of a multicenter, collaborative quality i
Autor:
Richard L. Weinberg, Robin B. Marsh, Hunter C. Gits, Matthew J. Schipper, Reshma Jagsi, Venkatesh L. Murthy, Lori J. Pierce, Ming Tang, Eleanor M. Walker, Corey Speers, James A. Hayman, James M. Balter, Carri K Glide-Hurst, Emily Morris, Mary Feng, Jean M. Moran
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 112:417-425
Purpose Radiation therapy (RT) can increase the risk of cardiac events in patients with breast cancer (BC), but biomarkers predicting risk for developing RT-induced cardiac disease are currently lacking. We report results from a prospective clinical
Autor:
Harvey J. Cohen, Noam A. VanderWalde, Jacqueline M. Lafky, Reshma Jagsi, Travis J. Dockter, Stuart M. Lichtman, Jeff A. Sloan, Jennifer Le-Rademacher, Daniel Satele, Daniel V. Wakefield, Rachel A. Freedman, Hyman B. Muss, Aminah Jatoi
Publikováno v:
J Geriatr Oncol
BACKGROUND: Older adults are under-represented in cancer clinical trials. However, it remains unclear which types of trials under-enroll aging patients. We aimed to identify associations between trial characteristics and disparate enrollment of older
Autor:
Marcia M. Russell, Mina S. Sedrak, Dominic Moon, Giby V. George, Genevieve Hollis, Martine Extermann, Fareeha Siddiqui, Sumi Misra, Amy L. Stella, Katherine Clifton, Ishwaria Mohan Subbiah, Louise C. Walter, William P. Tew, Liz Hollinger, Elizabeth R. Kessler, Reshma Jagsi, Grant R. Williams, Thuy T. Koll, Ilene S. Browner, Derek L. Stirewalt, Beatriz Korc-Grodzicki, Harvey J. Cohen, Sumati Gupta, Efrat Dotan, Cynthia Owusu, Hema Sundar, June M. McKoy, Joleen M. Hubbard, Ashley E. Rosko, Nancy L. Keating, Tracey O'Connor, Cary P. Gross
Publikováno v:
Journal of the National Comprehensive Cancer Network. 19:1006-1019
The NCCN Guidelines for Older Adult Oncology address specific issues related to the management of cancer in older adults, including screening and comprehensive geriatric assessment (CGA), assessing the risks and benefits of treatment, preventing or d
Autor:
Lori J. Pierce, G.S. Gustafson, T.P. Boike, James A. Hayman, Frank A. Vicini, Eleanor M. Walker, Kent A. Griffith, Jeffrey D. Radawski, Jean M. Moran, Michael M. Dominello, Reshma Jagsi
Publikováno v:
Cancer Research. 81:GS3-07
BACKGROUND: Evaluating whether physicians (MDs) accurately detect symptoms in patients (pts) is important because recognition of symptoms facilitates supportive care and because clinical trials often rely on MD assessments using the Common Toxicity C
Autor:
Rosie Bradley, Jeremy Braybrooke, Richard Gray, Robert Hills, Zulian Liu, Richard Peto, Lucy Davies, David Dodwell, Paul McGale, Hongchao Pan, Carolyn Taylor, Stewart Anderson, Richard Gelber, Luca Gianni, William Jacot, Heikki Joensuu, Alvaro Moreno-Aspitia, Martine Piccart, Michael Press, Edward Romond, Dennis Slamon, Vera Suman, Richard Berry, Clare Boddington, Mike Clarke, Christina Davies, Fran Duane, Vaughan Evans, Jo Gay, Lucy Gettins, Jon Godwin, Sam James, Hui Liu, Elizabeth MacKinnon, Gurdeep Mannu, Theresa McHugh, Philip Morris, Simon Read, Ewan Straiton, Yaochen Wang, John Crown, Evandro de Azambuja, Suzette Delaloge, Helena Fung, Charles Geyer, Marc Spielmann, Pinuccia Valagussa, Kathy Albain, Rodrigo Arriagada, John Bartlett, Elizabeth Bergsten-Nordström, Judith Bliss, Etienne Brain, Lisa Carey, Robert Coleman, Jack Cuzick, Nancy Davidson, Lucia Del Mastro, Angelo Di Leo, James Dignam, Mitch Dowsett, Bent Ejlertsen, Prue Francis, Michael Gnant, Matthew Goetz, Pam Goodwin, Pat Halpin-Murphy, Dan Hayes, Catherine Hill, Reshma Jagsi, Wolfgang Janni, Sibylle Loibl, Eleftherios P Mamounas, Miguel Martín, Hirofumi Mukai, Valentina Nekljudova, Larry Norton, Yasuo Ohashi, Lori Pierce, Philip Poortmans, Vinod Raina, Daniel Rea, Meredith Regan, John Robertson, Emiel Rutgers, Tanja Spanic, Joseph Sparano, Guenther Steger, Gong Tang, Masakazu Toi, Andrew Tutt, Giuseppe Viale, Xiang Wang, Tim Whelan, Nicholas Wilcken, Norman Wolmark, David Cameron, Jonas Bergh, Kathleen I Pritchard, Sandra M Swain
Publikováno v:
The Lancet. Oncology
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6
The lancet oncology
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) 2021, ' Trastuzumab for early-stage, HER2-positive breast cancer : a meta-analysis of 13 864 women in seven randomised trials ', The Lancet Oncology, vol. 22, no. 8, pp. 1139-1150 . https://doi.org/10.1016/S1470-2045(21)00288-6
Background: Trastuzumab targets the extracellular domain of the HER2 protein. Adding trastuzumab to chemotherapy for patients with early-stage, HER2-positive breast cancer reduces the risk of recurrence and death, but is associated with cardiac toxic
Autor:
Eleanor M. Walker, Kent A. Griffith, Lori J. Pierce, P.A. Paximadis, Jean M. Moran, Jeffrey D. Radawski, T.P. Boike, James A. Hayman, Jacob Burmeister, Inga S. Grills, Reshma Jagsi, Michael M. Dominello, Frank A. Vicini
Publikováno v:
J Clin Oncol
PURPOSE Understanding acute toxicities after whole-breast radiotherapy is important to inform patients, guide treatment decisions, and target supportive care. We evaluated patient-reported outcomes prospectively collected from a cohort of patients wi
Autor:
Susan K. Peterson, Sharon H. Giordano, Cameron W. Swanick, Grace L. Smith, Xiudong Lei, Kelly K. Hunt, Ying Xu, Simona F. Shaitelman, Reshma Jagsi, Kevin Diao, Sarah M. DeSnyder, Yu Shen, Mediget Teshome, Benjamin Smith
Publikováno v:
Ann Surg Oncol
The effect of surgeon factors on patient-reported quality-of-life outcomes after breast-conserving therapy (BCT) is unknown and may help patients make informed care decisions. We performed a survey study of women aged ≥ 67 years with non-metastatic
Autor:
Whitney H. Beeler, Shruti Jolly, Kent A. Griffith, James A. Hayman, Brandon R. Mancini, Michael M. Dominello, Lori J. Pierce, Jean M. Moran, T.P. Boike, L.A. Gharzai, Daniel E. Spratt, Reshma Jagsi
Publikováno v:
Practical Radiation Oncology. 9:e541-e548
Single-fraction (SF) radiation therapy is effective and convenient for patients with painful noncomplex bone metastases. Prior survey results reported a low recommendation of SF radiation therapy in the US. We sought to assess contemporary treatment